



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Wednesday, November 25, 2009

Bio-Technology General Corporation

[View the current Bio-Technology General Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/1938-Bio-Technology+General+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/1938-Bio-Technology+General+Corporation.html>)

Contact Details:

70 Wood Avenue South

Tel: 732 632 8800

Iselin

Fax: 732 632 8844

NJ

Email:

08830

United States of America

Bio-Technology General Corp. has established itself as a leader in the biopharmaceutical industry with superior capabilities in the research, development, and manufacturing of recombinant proteins, as well as capabilities in small molecule technology.

Through a combination of internal research and development, acquisitions, collaborative relationships, and licensing arrangements, we have successfully developed a diverse portfolio of therapeutic products directed at serving the underserved in both niche and wider markets.

Our goal is to leverage the scientific expertise and financial stability that we have achieved to date with our commercial products worldwide, to take advantage of new opportunities that will enable us to continue to seek out and provide solutions to some of the greatest health care challenges of today.

The company's corporate administration, licensing, human clinical studies, marketing and sales activities, quality assurance, and regulatory affairs are primarily coordinated at our headquarters in Iselin, New Jersey. Pre-clinical studies, research and development activities, and manufacturing of our biotechnology derived products are carried out through Bio-Technology General (Israel) Ltd., our wholly owned subsidiary, in Rehovot, Israel.

Recent Publications by Bio-Technology General Corporation:



- [Molecular characterization of a human monoclonal antibody that interacts with a sulfated tyrosine-containing epitope of the GPIIb receptor and inhibits platelet functions.](#)
*Modification of tyrosine residues in extracellular proteins by a sulfate...*24th February, 2006
Bio-Technology General (Israel) Ltd., Research Department, Kiryat Weizmann, - Mol Immunol. 2006 Feb;43(5):443-53. Epub 2005 Apr 7. ([DOI Direct Link](#))
- [Function-modulating human monoclonal antibodies against platelet-membrane receptors isolated from a phage-display library.](#)

Press Releases on Bio-Technology General Corporation:

FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review	24th November, 2009	Eisai Inc.	WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug
Quantros Licenses Adverse Event Identification Technology from University of Michigan	24th November, 2009	Quantros	SAN FRANCISCO, Nov. 24 /PRNewswire/ -- Quantros, a leading healthcare analytics and decision support software and services provider, announced today that it has licensed intellectual property and
IMAGINE Software Gains Record Number of New Clients Across United States	24th November, 2009	Technology Partners, Inc.	CHARLOTTE, N.C., Nov. 24 /PRNewswire/ -- Technology Partners, Inc. (dba IMAGINE Software), a leading provider of medical billing technology, announces today that it has recently been awarded nine new
BMP Sunstone to Present at Piper Jaffray Health Care Conference	24th November, 2009	BMP Sunstone Corporation	PLYMOUTH MEETING, Pa., Nov. 24 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that the Company will
BioMarin to Present at the NASDAQ OMX 23rd Investor Program	24th November, 2009	BioMarin Pharmaceutical Inc.	NOVATO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company

BioNews Results for Bio-Technology General Corporation



- [Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA](#)

- SmartBrief: Oct 29 2009 7:16AM Matching: bio technology general*
- [AusBiotech 2009: Int'l Biotech Showcase Has Begun](#)
Scoop: Oct 28 2009 1:51AM Matching: bio technology general
 - [Savient Pharmaceuticals Inc - SWOT Analysis](#)
TMC Net: Oct 24 2009 6:43PM Matching: bio technology general
 - [Universal Detection Technology Anthrax Detection Equipment Approved on New York State H.I.R.E. Contract, Distr](#)
Freshnews.com: Oct 20 2009 10:12AM Matching: bio technology general
 - [Universal Detection Technology Anthrax Detection Equipment Approved on New York State H.I.R.E. Contract, Distr](#)
Genetic Engineering News: Oct 20 2009 9:46AM Matching: bio technology general
 - [Universal Detection Technology Anthrax Detection Approved on New York State H.I.R.E. Contract, Distributed by](#)
Genetic Engineering News: Oct 19 2009 9:28PM Matching: bio technology general

Bio-Technology General Corporation Patents:



- 5198361- [Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods](#)
- 5527691- [Expression vectors containing lambdapl promoter and T.sub.1 T.sub.2 rRNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and related methods](#)
- 5540911- [Methods of use of human manganese superoxide dismutase](#)
- 5548068- [Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations](#)
- 5593860- [Expression plasmids containing the deo promoter, and bacterial hosts containing the plasmids](#)
- 5637495- [Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods](#)
- 5670371- [Bacterial expression of superoxide dismutase](#)
- 5679320- [Fibrin binding domain polypeptides and uses and methods of producing same](#)
- 5759816- [Expression vectors containing .lambda.P.sub.L promoter and T.sub.1 T.sub.2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods](#)
- 5763215- [Method of removing N-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby](#)
- 5783421- [DNA encoding novel polypeptide having Factor Xa inhibitory activity](#)
- 5525472- [Method for production and purification or recombinant Apolipoprotein E from bacteria](#)
- 5457042- [Sod polypeptide analogs](#)
- 5242812- [Method for production and purification of hepatitis B vaccine](#)
- 5246847- [Polypeptide analogs of human manganese superoxide dismutase and compositions and complexes thereof](#)
- 5248604- [Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof](#)
- 5256546- [Bacterial expression of porcine growth hormone](#)

- [5264211- Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation](#)
- [5270030- Fibrin binding domain polypeptide and method of producing](#)
- [5270195- Plasmids for expression and method of producing a human manganese superoxide dimutase analog](#)
- [5360729- Method for purification of recombinant copper/zinc \(CU-ZN\) superoxide dismutase from bacteria or eucaryotic cells](#)
- [5455029- Therapeutic compositions comprising a mixture of human CuZn superoxide dismutase analogs](#)
- [5455158- Fibrin binding domain polypeptides and uses and methods of producing same](#)
- [5795776- Expression plasmids regulated by an OSMB promoter](#)
- [5801017- Production of recombinant factor Xa inhibitor of leech Hirudo medicinalis](#)
- [6008193- Methods of using human von Willebrand factor GPIb binding domain polypeptides](#)
- [6010875- Expressions plasmids containing the deo promoter, and bacterial hosts containing the plasmids](#)
- [6030611- Therapeutic SOD compositions and uses thereof](#)
- [6054291- Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods](#)
- [6121426- Fibrin binding domain polypeptides and uses and methods of producing same](#)
- [6211341- Polypeptide having factor Xa inhibitory activity](#)
- [6361772- Human manganese superoxide dismutase DNA, its expression and method of recovering human manganese superoxide dismutase](#)
- [6576659- Use of oxandrolone in the treatment of burns an other wounds](#)
- [6610520- Gene encoding human manganese superoxide dismutase and recombinant polypeptide encoded thereby](#)
- [6670351- Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1](#)
- [6001604- Refolding of proinsulins without addition of reducing agents](#)
- [5965383- Fibrin binding domain polypeptides and uses and methods of producing same](#)
- [5824641- Method of treating of preventing influenza](#)
- [5837488- Cloning and production of human von Willebrand Factor GP1b binding domain polypeptides and methods of using same](#)
- [5849536- Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same](#)
- [5849702- Cloning and production of human von Willebrand factor GPIB binding domain polypeptides and methods of using same](#)
- [5858970- Polypeptide having Factor Xa inhibitory activity](#)
- [5863534- Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity](#)
- [5869616- Fibrin binding domain polypeptides and uses and methods of producing same](#)
- [5872147- Use of oxandrolone in the treatment of chronic obstructive pulmonary disease](#)
- [5945304- Expression plasmids regulated by an osmB promoter](#)
- [5948668- Production of enzymatically active recombinant carboxypeptidase B](#)
- [7132510- Specific human antibodies for selective cancer therapy](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

